# Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)

> **NCT00640523** · PHASE2 · COMPLETED · sponsor: **BioCryst Pharmaceuticals** · enrollment: 23 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)

## Interventions

- **DRUG:** forodesine HCl

## Key facts

- **NCT ID:** NCT00640523
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2010-11
- **Final completion:** 2011-11
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2012-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00640523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00640523, "Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00640523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*